Skip to main content
SpringerLink
Log in

Current Understanding of Colorectal Neoplasia

  • Chapter
Colonic Diseases

  • 240 Accesses

Abstract

Colorectal cancer is the second most common cause of cancer-related death in the United States. For the year 2000, an estimated 130,200 new cases will be diagnosed (93,800 colon cancers and 36,400 rectal cancers) with 56,300 deaths expected in that year. Colorectal cancer accounts for 11% of all cancer deaths in the United States (Surveillance, Epidemiology, and End Results [SEER] 2000 data, see Website: www.seer.cancer.gov). Of note, incidence rates declined by 2.1% between 1992 and 1996, and recent data suggest that mortality rates for colorectal cancer may also be declining. These trends may be attributable to increased screening efforts, “prophylactic polypectomy,” and improved adjuvant therapies and should bolster even greater efforts in detection, prevention, and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen AM, Minsky B, Schilsky RL. Cancer of the colon. Cancer Principles and Practice of Oncology. 5th ed., DeVita VT, Hellman S, Rosenberg S. (eds.), Lippincott-Raven, Philadelphia, PA, 1997.

    Google Scholar 

  2. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319 (1988) 525–532.

    Article  PubMed  CAS  Google Scholar 

  3. Winawer SJ, Zauber AG, O’Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N. Engl. J. Med., 328 (1993) 901–906.

    Article  PubMed  CAS  Google Scholar 

  4. Houlston RS, Collins A, Slack J, et al. Dominant genes for colorectal cancer are not rare. Ann. Hum. Genet., 56 (1992) 99–103.

    Article  PubMed  CAS  Google Scholar 

  5. Giovannucci E, Colditz GA, Stampfer MJ, et al., A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J. Natl. Cancer Inst., 86 (1994) 183–191.

    Article  PubMed  CAS  Google Scholar 

  6. Slattery ML, Edwards SL, Boucher KM, Anderson K, Caan BJ, et al. Lifestyle and colon cancer: an assessment of factors associated with risk. Am. J. Epidemiol., 150 (1999) 869–877.

    Article  PubMed  CAS  Google Scholar 

  7. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N. Engl. J. Med., 340 (1999) 169–176.

    Article  PubMed  CAS  Google Scholar 

  8. Imperiali G, Minoli G. Colonic neoplasm in asymptomatic patients with family history of colon cancer: results of a colonoscopic prospective and controlled study. Results of a pilot study of endoscopic screening of first degree relatives of colorectal cancer patients in Italy. Gastrointest. Endosc., 49 (1999) 132–133.

    PubMed  CAS  Google Scholar 

  9. Lynch HT, Lynch J. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology, 104 (1993) 1535–1549.

    PubMed  CAS  Google Scholar 

  10. Lynch HT, Smyrk TC, Lanspa SJ, et al. Upper gastrointestinal manifestations in families with hereditary flat adenoma syndrome. Cancer, 71 (1993) 2709–2714.

    Article  PubMed  CAS  Google Scholar 

  11. Vogelstein B. Genetic testings for cancer: the surgeon’ s critical role. In 26th Annula Meeting of the American College of Surgeons. Elsevier Science, Baltimore, MD, 1998.

    Google Scholar 

  12. Lynch PM, Wargovich MJ, Lynch HT, et al. A follow-up study of colonic epithelial proliferation as a biomarker ina Native-American family with hereditary nonpolyposis colon cancer. J. Natl. Cancer Inst., 83 (1991) 951–954.

    Article  PubMed  CAS  Google Scholar 

  13. Leach FS, Nicolaides NC, Papadopoulas N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75 (1993) 1215–1225.

    Article  PubMed  CAS  Google Scholar 

  14. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature, 368 (1994) 258–261.

    Article  PubMed  CAS  Google Scholar 

  15. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev., 3 (1984) 303–324.

    Article  PubMed  CAS  Google Scholar 

  16. Mandel JS, Bond JH, Bradley M, et al. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota’s Colon Cancer Control Study. Gastroenterology, 97 (1989) 597–600.

    PubMed  CAS  Google Scholar 

  17. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med., 328 (1993) 1365–1371.

    Article  PubMed  CAS  Google Scholar 

  18. Kewenter J. [Does screening influence mortality of colorectal cancer?]. Lakartidningen,88 (1991) 601–602.

    Google Scholar 

  19. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann. Intern. Med., 126 (1997) 811–822.

    PubMed  CAS  Google Scholar 

  20. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewall H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N. Engl. J. Med., 343 (2000) 162–168.

    Article  PubMed  CAS  Google Scholar 

  21. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N. Engl. J. Med., 332 (1995) 861–867.

    Article  PubMed  CAS  Google Scholar 

  22. Lynch HT, Lynch JF. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet. Cytogenet., 53 (1991) 143–160.

    Article  PubMed  CAS  Google Scholar 

  23. Bruckner HW, Pitrelli J, Merrick M. Cancer Medicine. 5th ed., Bast R. (ed.), B.C. Decker, Hamilton, Ontario, Canada, 2000.

    Google Scholar 

  24. Wexner SD, Cohen SM, Johansen OB, Nogueras JJ, Jagelman DG. Laparoscopie colorectal surgery: a prospective assessment and current perspective. Br. J. Surg., 80 (1993) 1602–1605.

    Article  PubMed  CAS  Google Scholar 

  25. Crane CH, Janjan NA, Abbruzzese JL, et al. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int. J. Radiat. Oncol. Biol. Phys., 49 (2001) 107–116.

    Article  PubMed  CAS  Google Scholar 

  26. Minsky BD, Cohen AM, Kemeny M, et al. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J. Clin. Oncol., 10 (1992) 1218–1224.

    PubMed  CAS  Google Scholar 

  27. Janjan NA, Crane CN, Feig BW, et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.,47 (2000)713–718.

    Google Scholar 

  28. Wolmark N, Wieand S, Rockette HE, et al., The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann. Surg., 198 (1983) 743–752.

    Article  PubMed  CAS  Google Scholar 

  29. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J. Clin. Oncol., 8 (1990) 1466–1475.

    PubMed  CAS  Google Scholar 

  30. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol., 17 (1999) 1349–1355.

    PubMed  CAS  Google Scholar 

  31. Wolmark N, Rockette H, Mamanas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol., 17 (1999) 3553–3559.

    PubMed  CAS  Google Scholar 

  32. Poon MA, O’Connell MJ, Wienad HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., (1991) 9 1967–1972.

    PubMed  CAS  Google Scholar 

  33. Moore HC, Haller DG. Adjuvant therapy of colon cancer. Semin. Oncol., 26 (1999) 545–555.

    PubMed  CAS  Google Scholar 

  34. NIH. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA, 264 (1990) 1444–1450.

    Article  Google Scholar 

  35. GTSG. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N. Engl. J. Med., 312 (1985) 1465–1472.

    Article  Google Scholar 

  36. O’Connell MJ, martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med., 331 (1994) 502–507.

    Article  PubMed  Google Scholar 

  37. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol., 150 (1986) 195–203.

    Article  PubMed  CAS  Google Scholar 

  38. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J. Clin. Oncol., 18 (2000) 243–254.

    PubMed  CAS  Google Scholar 

  39. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Nakajima N. Adjuvant regional chemotherapy after hepatic resection for colorectal metastases. Br. J. Surg., 86 (1999) 1025–1031.

    Article  PubMed  CAS  Google Scholar 

  40. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med., 341 (1999) 2039–2048.

    Article  PubMed  CAS  Google Scholar 

  41. NGTATG. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J. Clin. Oncol., 10 (1992) 904–911.

    Google Scholar 

  42. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 14 (1996) 709–715.

    PubMed  CAS  Google Scholar 

  43. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343 (2000) 905–914.

    Article  PubMed  CAS  Google Scholar 

  44. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352 (1998) 1413–1418.

    Article  PubMed  CAS  Google Scholar 

  45. Ducreux M, Gil-Delgado M, Andre T, Ychou M, de Gramond A, Khayat D. [Irinotecan in combination for colon cancer]. Bull. Cancer, Spec No (1998) 43–46.

    Google Scholar 

  46. Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43 (1989) 237–250.

    Article  PubMed  CAS  Google Scholar 

  47. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-1–1,2- diaminocyclohexane)platinum (II): new experimental data. Biomed. Pharmacother., 43 (1989) 251–260.

    Article  PubMed  CAS  Google Scholar 

  48. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol., 17 (1999) 3560–3568.

    PubMed  CAS  Google Scholar 

  49. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 18 (2000) 136–147.

    PubMed  CAS  Google Scholar 

  50. Levi F, Giachetti S, Adam R, Zidani R, Metzger G, Misset JL. Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Eur. J. Cancer, 31A (1995) 1264–1270.

    Article  Google Scholar 

  51. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 18 (2000) 2938–2947.

    PubMed  Google Scholar 

  52. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N. Engl. J. Med., 342 (2000) 1960–1968.

    Article  PubMed  CAS  Google Scholar 

  53. Benito E, Stiggelbout A, Boxch FX, et al. Nutritional factors in colorectal cancer risk: a case-control study in Majorca. Int. J. Cancer, 49 (1991) 161–167.

    Article  PubMed  CAS  Google Scholar 

  54. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J. Natl. Cancer Inst., 85 (1993) 875–884.

    Article  PubMed  CAS  Google Scholar 

  55. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methioninelow-folate diets, and risk of colon cancer in men. J. Natl. Cancer Inst., 87 (1995) 265–273.

    Article  PubMed  CAS  Google Scholar 

  56. Baron JA, Sandler RS, Haile RW, Mandel JS, Mott LA, Greenberg ER. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J. Natl. Cancer Inst., 90 (1998) 57–62.

    Article  PubMed  CAS  Google Scholar 

  57. Ferraroni M, LaVecchia C, D’ Avanzo B, Negri E, Franceschi S, Decarii A. Selected micronutrient intake and the risk of colorectal cancer. Br. J. Cancer, 70 (1994) 1150–1155.

    Article  PubMed  CAS  Google Scholar 

  58. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107 (1994) 1183–1188.

    PubMed  CAS  Google Scholar 

  59. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342 (2000) 1946–1952.

    Article  PubMed  CAS  Google Scholar 

  60. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology, 112 (1997) 594–642.

    Article  PubMed  CAS  Google Scholar 

  61. Fleming ID, Cooper JS, Henson DE, American Joint Committee on Cancer, Cancer Staging Manual. 5th ed., Lippincott-Raven, Philadelphia, PA, 1997.

    Google Scholar 

Download references

Authors
  1. Melanie B. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA

    Timothy R. Koch MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Thomas, M.B., Wolff, R.A. (2003). Current Understanding of Colorectal Neoplasia. In: Koch, T.R. (eds) Colonic Diseases. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-314-9_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-314-9_26

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9740-3

  • Online ISBN: 978-1-59259-314-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation